Assistive Technology Alternative Financing Program
- Response deadline
- Jul 22, 2026 Closed
- Date posted
- Jun 22, 2026
- Source
- Open notice
Description
The purpose of the Assistive Technology (AT) Alternative Financing Program (AFP) is to support programs that provide for the purchase of AT, such as a low-interest loan fund, an interest buy-down program, a revolving loan fund, a loan guarantee, or an insurance program, that results in the acquisition of AT devices and services. Applicants for the AT AFP grant awards are required to provide an assurance that, and information describing the manner in which, the AT AFP will expand and emphasize consumer choice and control. Applicants should incorporate credit-building activities in their programs, including financial education and information about other possible funding sources. Successful applicants must emphasize consumer choice and control and build programs that will provide financing for the full array of AT devices and services and ensure that all people with disabilities, regardless of type of disability or health condition, age, level of income, and residence, have access to the program.
Classifications
- NAICS93.469
Documents (1)
- Downloadhhs-2026-acl-cip-attf-0067.pdfapplication/pdf250 KB
Contacts
Similar contracts
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food SpecimensDue Apr 1, 2027
- Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not AllowedDue Apr 1, 2027
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)Due Jul 14, 2026
- Environmental influences on Child Health Outcomes (ECHO) Cohort Data and Biospecimen Access (X01 Clinical Trial Not Allowed)Due Mar 1, 2028
- NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)Due May 7, 2028